GlassScriptPhysician profile
Melissa D Larsen
NPI 1992103386
$4,055.74
in general payments reported to CMS, 2019-2025
12 companies · $711 in 2025
The $711 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,344 · 2022: $558 · 2023: $738 · 2024: $705 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,192.59 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $1,072.07 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $607.02 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $330.33 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $284.75 | 2021-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $163.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.83 | 2025 | Cobenfy |
| Lundbeck LLC | $96.30 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $83.81 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $60.09 | 2024-2025 | Entyvio |
| Vanda Pharmaceuticals INC. | $28.90 | 2021 | |
| Allergan, INC. | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.